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The largest carnivorous marsupial in Australia, the Tasmanian devil (Sarcophilus harrisii ) is
facing extinction in the wild due to a transmissible cancer known as Devil Facial Tumour
Disease (DFTD). DFTD is a clonal cell line transmitted from host to host with 100% mortal-
ity and no known immunity. While it was first considered that low genetic diversity of the
population of devils enabled the allograft transmission of DFTD recent evidence reveals
that genetically diverse animals succumb to the disease. The lack of an immune response
against the DFTD tumor cells may be due to a lack of immunogenicity of the tumor cells.This
could facilitate transmission between devils. To test immunogenicity, mice were injected
with viable DFTD cells and anti-DFTD immune responses analyzed. A range of antibody
isotypes against DFTD cells was detected, indicating that as DFTD cells can induce an
immune response they are immunogenic. This was supported by cytokine production,
when splenocytes from mice injected with DFTD cells were cultured in vitro with DFTD
cells and the supernatant analyzed. There was a significant production of IFN-γ and TNF-α
following the first injection with DFTD cells and a significant production of IL-6 and IL-10 fol-
lowing the second injection. Splenocytes from naïve or immunized mice killed DFTD cells
in in vitro cytotoxicity assays.Thus, they are also targets for immunological destruction.We
conclude that as an immune response can be generated against DFTD cells they would
be suitable targets for a vaccine.
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INTRODUCTION
The Tasmanian devil (Sarcophilus harrisii) faces possible extinc-
tion in the wild due to a transmissible cancer known as Devil Facial
Tumour Disease (DFTD). Genetic and chromosomal research has
provided convincing evidence that the malignant neoplasm orig-
inated in an individual female Tasmanian devil (1). While it was
first considered that low genetic diversity of the population of
devils, from which the DFTD founder was derived, enabled the
establishment of DFTD throughout subsequent devil populations
(2, 3), recent evidence reveals that genetically diverse animals are
prone to the disease (4).
The unique and conserved chromosomal rearrangements of
DFTD cells compared to the host’s negate the possibility of trans-
mission from a viral or bacterial agent, pollutants or toxins in the
environment. DFTD is described, alongside the canine transmis-
sible venereal tumor (CTVT), as a clonal cell line immortalized as
a parasitic infectious allograft (5). Not only did the DFTD cancer
cells evade the original host’s immune system but the immune sys-
tems of subsequent devils. The cancer cells are transmitted through
facial biting of successive hosts (1, 6, 7).
A lack of immunogenicity is one possible mechanism for DFTD
cells to evade the immune system. A failure to present tumor anti-
gens to the immune system would facilitate transmission between
devils. Siddle et al. (8) revealed that DFTD cells do not express
cell surface MHC molecules in vitro or in vivo. The genes essen-
tial to the antigen-processing pathway, such as β2-microglobulin
and transporters associated with antigen processing are down-
regulated. The loss of gene expression is not due to structural
mutations, but to regulatory changes including epigenetic deacety-
lation of histones (8). By down-regulating MHC, the tumor cells
remain invisible to the devils’ immune system. But even in the
absence of MHC expression, there should be enough protein
differences to induce an immune response following allogenic
transfer.
In order to develop an effective vaccine or immunother-
apy, it is important to understand the mechanisms that shield
this tumor from immunosurveillance. Ideally, an immunolog-
ical study of an allograft tumor in the host species is neces-
sary, but in the case of the Tasmanian devil conducting large
scale immunological experiments are not possible due to the
endangered species status. Therefore, since it is widely accepted
that mouse models provide valuable insights into the study
of human cancers our investigation exploits a mouse model
to study DFTD. The particular advantage of a mouse model
is the readily available antibodies to detect mouse immune
system responses while there is a paucity of equivalent anti-
bodies currently available for the Tasmanian devil immune
system.
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To determine if DFTD cells are immunogenic and therefore
potential targets for immunotherapy, we used a mouse model
developed in our laboratory to examine DFTD. We have previously
shown that the tumors successfully implant in immunocompro-
mised NOD/SCID mice but do not implant in immunocompetent
BALB/c and C57BL/6 mice. The aim was to determine if this rejec-
tion by immunocompetent mice was an active immunological
response and not due to other factors such as preformed anti-
bodies commonly associated with xenogeneic graft rejection. This
was performed by examining specific antibody, cytokine, and cell
mediated cytotoxicity responses to the DFTD xenograft.
In addition, this xenograft model was used to investigate the
possibility that if DFTD cells are immunogenic they may polarize
the murine immune system toward a TH2 response. This is a mech-
anism exploited by tumor cells to subvert anti-tumor immune
responses toward ineffective humoral responses (9).
MATERIALS AND METHODS
MICE
All mice were obtained from the University of Tasmania Central
Animal House and housed in a pathogen free environment and
provided with food and water ad libitum. The two strains used
were C57BL/6 and BALB/c. The mice were at least 5 weeks old at
commencement of experimental treatments.
All animal experiments were performed with approval of the
Animal Ethics Committee of University of Tasmania (UTAS),
approval numbers A0010231 and A0010888.
CELL LINES AND CULTURE MEDIA
Devil Facial Tumour Disease cell line, C5065, was obtained from
stocks stored in liquid nitrogen at the UTAS. The cell line was
established from primary tumor biopsy samples taken under the
approval of the Animal Ethics Committee of Tasmania’s Park and
Wildlife Services (permit numbers 33/2004–5 and 32/2005–6) and
provided by A.-M. Pearse and K. Swift, Tasmanian Department of
Primary Industries, Parks, Wildlife and Environment (DPIPWE).
Cells were grown in RPMI-10FCS, which consisted of RPMI-1640
medium (GIBCO, New York, USA) supplemented with 10% fetal
calf serum (FCS) (Bovogen Biological, VIC, Australia), 5 mM l-
glutamine (Sigma-Aldrich, St Louis, MO, USA), and 40 mg/ml of
gentamicin (Pfizer, Bentley Australia). The C5065 cell line culture
was maintained in a fully humidified 5% CO2 incubator at 35°C.
Assays required co-culturing of mouse splenocytes with C5065
were maintained at 37°C.
INDIRECT IMMUNOFLUORESCENCE ASSAY FOR DETECTION OF
ANTIBODIES BY FLOW CYTOMETRY
Blood was collected from mice post mortem via cardiac puncture
or via mandible bleed with living mice, allowed to clot and the
serum was separated by centrifuging. Serum was stored at −20
or −80°C until required. One microliter of each serum sample
was incubated with 105 DFTD cells in 50µl of staining buffer
[phosphate-buffered saline (PBS) with 1% (w/v) bovine serum
albumin (BSA) (Roche Diagnostics, Germany) and 0.01% NaN3],
on ice for 30 min. Following two washes with PBS, the cells were
incubated with 2µg of the relevant anti-mouse immunoglobulin
Alexa-fluor conjugated antibody (Life Technologies, USA, catalog
numbers IgG A-31553, IgG1 A-21121, IgG2a A-21136, IgG2b A-
21146, IgG3 A-21151, IgM A-21042) in 100µl of staining buffer
on ice for 30 min. Negative controls included DFTD cells with
either no serum or pooled naïve serum. Following three washes in
PBS, the samples were resuspended in 100µl of PBS for prompt
reading on the flow cytometer (BD Canto II, Becton Dickinson,
NJ, USA).
The forward scatter, side scatter, thresholds, and PMT voltages
were optimized to place the negative mean fluorescence inten-
sity (MFI) for the negative controls at approximately the second
decade of the log scale. FCS 4 Express Flow Cytometry software
(De nova Software, USA) was used to perform histogram overlays
to compare indirect immunofluorescence levels of samples with
naïve serum control. The geometric mean of the MFI for immune
serum was divided by the geometric mean of the MFI for naïve
serum control to give the relative antibody levels.
IMMUNIZATIONS
Devil Facial Tumour Disease cells in log growth phase were har-
vested from culture and viability was ascertained by trypan blue
exclusion. Cell viability ranged from 50 to 80%. Cells were washed,
resuspended in PBS, and 2× 106 viable cells were injected via
the subcutaneous (SC) route or intraperitoneal (IP) route into
C57BL/6 and BALB/c mice. With multiple sites SC injections, the
cells were divided between multiple sites as stated. No adjuvants
were used.
MOUSE MONONUCLEAR CELLS FOR IN VITRO CYTOKINE AND
CYTOTOXICITY ASSAYS
Spleens were removed from naïve or IP immunized mice. Lymph
nodes were obtained from SC immunized mice. Mononuclear
cells (MNC) were obtained by pressing spleens or lymph nodes
through 40µm cell strainers (BD Falcon, USA) and then separat-
ing them by density-gradient centrifugation on Histopaque-1083
gradient (Sigma-Aldrich, USA) following the manufacturer’s pro-
tocol. The MNC were washed twice with PBS and resuspended in
RPMI-10FCS for use in in vitro cytotoxicity and cytokine assays.
IN VITRO CYTOKINE CULTURES FROM SPLENOCYTE SUPERNATANTS
Mononuclear cells were prepared as described above and resus-
pended in RPMI-10FCS at 107 cells/ml. DFTD cells were harvested
and resuspended at 105 cells/ml in RPMI-10FCS. One hundred
microliters each of DFTD and lymphocyte suspensions were com-
bined in V-bottomed 96 well plates (Greiner Bio-one, Fricken-
hausen, Germany). Control wells were also prepared in the same
plate by combining 100µl RPMI with 100µl of either DFTD or
MNC as indicated. The plates were covered by lids and incubated
for 72 h at 37°C with 5% CO2. The plates were centrifuged to pel-
let the cells and the supernatant collected and stored at −20°C
until required. Supernatant samples were assayed individually for
cytokine activity using BD Biosciences CBA TH1, TH2, TH17
micro-bead array kit and FACS array software as per manufac-
turer’s instruction (BD Biosciences, Cat # 560485). In brief, 50µl
of each supernatant sample and cytokine standards were incu-
bated with mixed capture beads and PE detection reagent for 3 h,
washed, resuspended, and run on the BD Canto II, flow cytome-
ter. Cytokine data were analyzed using FCAP Array software (BD
Bioscience, San Jose, CA, USA).
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CYTOTOXICITY ASSAY USING IMMUNOFLUORESCENCE DOUBLE
STAINING PROTOCOL
DFTD (107; target cells) were labeled with 5(6)-Carboxyfluorescein
diacetate N-succinimidyl ester (CFSE) by incubating with 2µl of
5 mM CFSE for 30 min at 23°C on shaker plate protected from
light. Cells were washed twice and resuspended at 105 cells/ml in
RPMI-10FCS.
Mononuclear cells were resuspended in RPMI-10FCS at 107
cells/ml. A V-bottomed 96 well plate (Greiner Bio-one, Fricken-
hausen, Germany) was prepared with 100µl serial dilutions of the
MNC to provide effector ratios of 100:1, 50:1, 25:1, 12:1, 6:1, and
3:1 with 104 target cells.
The cytotoxicity assays were performed using four replicate
samples and incubating for 18 h at 37°C in a fully humidified 5%
CO2 incubator. The plates were centrifuged for 5 min at 500 g,
supernatant removed, pellet resuspended in 100µl PBS+ 1µl
propidium iodide (PI), and read on a BD Canto II flow cytome-
ter with the High Throughput Sampler unit directly recovering
samples from the wells.
Flow cytometry data analysis was performed using Flowing
Software (Turku Centre for Biotechnology, Finland), or FCS 4
Express Flow Cytometry (De Nova Software, USA), with fur-
ther analysis and graphs produced in Microsoft Excel 2007 and
GraphPad Prism 5.
Cells positive for CFSE and PI were identified as dead target cells
whereas cells positive for CFSE, but negative for PI, were identified
as viable target cells. Cytotoxicity per well was calculated as dead
target cells divided by the sum of dead and viable target cells and
expressed as a percentage. The average cytotoxicity for each effec-
tor target ratio was calculated and the standard error of the mean
(SEM) values was used for the error bars.
STATISTICAL ANALYSES
Quantitative data comparing two groups are expressed as the
mean± SEM and P-values calculated using Student’s unpaired
two tailed t -test. Quantitative data comparing more than two
groups are expressed as the mean with the probability calculated
by one-way ANOVA followed by Dunnett’s test.
RESULTS
NAÏVE BALB/c AND C57/BL6 MICE HAVE BARELY DETECTABLE LEVELS
OF PREFORMED ANTIBODIES BUT FOLLOWING IMMUNIZATON HAVE
HIGH LEVELS OF SPECIFIC ANTIBODIES
There was no evidence for substantial levels of preformed anti-
bodies as serum from naïve mice showed minimal binding to
DFTD cells. This was the case for both IgG and IgM. As shown
in Figure 1, flow cytometry profiles of serum from three represen-
tative naïve BALB/c and C57/BL6 mice show barely detectable
levels of preformed antibodies. When immunized intraperi-
toneally, both strains of mice had considerable increases in lev-
els of specific antibodies to DFTD cells. As future experiments
were aimed at evaluating specific immunity following DFTD
cell immunization, the results were summarized as histograms
rather than displaying multiple flow cytometry plots. The geo-
metric mean of the MFI of the serum from immunized mice was
divided by the geometric mean of the MFI of the serum from
naïve mice.
SUBCUTANEOUS INJECTIONS OF BALB/c MICE WITH DFTD CELLS
INDUCES ANTIBODY PRODUCTION
BALB/c mice were twice injected subcutaneously with viable
DFTD cells, which were obtained from cell culture. The objec-
tive was to determine if living DFTD cells could elicit an anti-
body response. Flow cytometry was used to analyze serum for
IgG and IgM antibodies specific to DFTD surface antigens. All
the IgG isotypes tested for were detected, but IgM was not
detected (Figure 2), thus indicating that DFTD cells can induce
an antibody response. The responses to single site SC injec-
tions were compared with multiple site SC injections to deter-
mine if multiple site injections with the same number of total
cells produced a greater response. Multiple site SC injections
produced greater total IgG (P < 0.05; unpaired Student’s t -test)
and IgG1 (P < 0.01; unpaired Student’s t -test) responses than
injecting the same number of DFTD cells into a single site
(Figure 2).
INTRAPERITONEAL INJECTIONS OF C57BL/6 MICE WITH DFTD CELLS
INDUCE GREATER ANTIBODY RESPONSES THAN SC INJECTIONS
C57BL/6 mice were intraperitoneally or subcutaneously injected
twice with viable DFTD cells. The objective was to determine,
which route produced a better antibody response. Results in
Figure 3 show that the IP route produced both IgM and IgG anti-
bodies. The responses following the IP injections were stronger
than the SC route for IgM (P < 0.01; unpaired Student’s t -test),
total IgG, IgG1, IgG2a (P < 0.001; unpaired Student’s t -tests), and
IgG3 (P < 0.05; unpaired Student’s t -test).
A SINGLE INTRAPERITONEAL INJECTION OF C57BL/6 MICE WITH DFTD
CELLS INDUCES BOTH IgM AND IgG ANTIBODY RESPONSES WITHIN
7 DAYS
Having established that immunization with DFTD cells induces
strong IgG responses following two injections, we next determined
if IgG and IgM responses could be detected after a single injection.
Results in Figure 4 show 4 days was insufficient to generate opti-
mum levels of antibody in the serum with IgM detected in only two
of the four mice and IgG detected in only one of these two mice.
By 7 days all mice produced both IgM and IgG antibodies with
the predominant isotype being IgG (P < 0.05; Student’s unpaired
t -test) (Figure 4).
SECONDARY ANTIBODY RESPONSES DEMONSTRATE ENHANCED
MEMORY RESPONSES FOR IgG BUT NOT IgM
Responses to secondary immunizations following 95 days showed
enhanced responses in IgG1, IgG2b, and IgG3 antibodies but not
IgM (Figures 4 and 5). The enhanced response is consistent with a
primed immune system memory response because it was evident
95 days after the primary immunization.
INTRAPERITONEAL INJECTIONS OF DFTD CELLS DO NOT INDUCE
GREATER CYTOTOXICITY IN SPLENOCYTES THAN THOSE OBTAINED
FROM NAÏVE MICE
As IP injections of DFTD cells produced the best antibody
response, we used this route to determine if an enhanced cytotoxic
response could be induced against DFTD cells. Splenocytes from
naïve C57BL/6 mice demonstrated dose response cytotoxicity
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FIGURE 1 | Serum from three naïve BALB/c mice (upper panel) and three
naïve C57/BL6 mice (middle panel) were analyzed for preformed IgM
(left panel) and preformed IgG (right panel) antibodies that bound DFTD
cells. Three BALB/c mice were then immunized intraperitoneally with DFTD
cells and specific IgM and IgG antibodies were analyzed (lower panel).
Shaded areas represent no primary antibody, solid black lines represents
isotype (IgM or IgG) control, blue lines represent IgM anti-DFTD antibodies,
red lines represent IgG anti-DFTD; lower panel, dotted lines represent serum
from naïve mice, solid lines represent serum from mice immunized
intraperitoneally with DFTD.
against DFTD cells following 18 h incubation (Figure 6). This
was not improved following two IP injections with DFTD cells,
indicating that unprimed cells of the immune system mediated
the cytotoxicity.
IMMUNIZATION WITH DFTD CELLS DOES NOT BIAS ANTIBODY OR
CYTOKINE RESPONSES TOWARD A TH2 PROFILE
Since tumor cells can weaken anti-tumor immune responses by
skewing them toward less effective TH2 responses, we examined
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FIGURE 2 | Comparison of antibody responses of BALB/c mice injected
twice subcutaneously with 106 DFTD cells into a single site, or divided
equally between two sites on days 0 and 16, with serum collected day
25. Mean fluorescence intensity ratio of samples compared to pooled naïve
mouse serum was used as a relative measure of antibody production. IgM
was not detected in any sample (Data are expressed as mean±SEM;
probability calculated by an unpaired Student’s t -test *P <0.05,
**P < 0.01).
FIGURE 3 | Comparison of antibody responses for intraperitoneal and
multiple sites subcutaneous injections with DFTD cells. Mean
fluorescence intensity ratio of samples compared to pooled naïve mouse
serum was used as a relative measure of antibody expression. C57BL/6
mice were injected with 106 DFTD cells on day 0 and 16 with serum
collected on day 25. The SC cohort received SC injections divided between
the neck and rump region to target multiple draining lymph nodes (Data are
expressed as mean±SEM; probability calculated by an unpaired Student’s
t -test, *P <0.05, **P <0.01, and ***P <0.001).
the antibody and cytokine profiles for such a bias. Two strains
of mice were compared because of their reportedly oppos-
ing TH1 (C57BL/6) or TH2 (BALB/c) dominated immune
responses (10, 11).
FIGURE 4 | C57BL/6 mice were injected IP with 106 DFTD cells and
serum was collected 4 and 7days post injection. All samples were
analyzed in the same flow cytometry experiment to permit direct
comparison of mouse anti-DFTD IgG and IgM in the serum. Mean
fluorescence intensity ratio of samples compared to pooled naïve mouse
serum was used as a relative measure of antibody expression. There was
no significant difference in the mean of IgM expression for all four mice
(represented by different plot symbols) compared on days 4 and 7 post
injection. There was a significant difference of IgG expression between
days 4 and 7 (P <0.05; probability calculated by a paired Student’s t -test).
Mice were injected intraperitoneally twice with DFTD cells and
serum was collected 7–8 days following the second immunization.
Levels of IgM, the TH2 antibody, IgG1, and the TH1 antibody IgG3
were not significantly different between the two strains (Figure 7).
Of the other TH1 antibodies, BALB/c mice expressed higher lev-
els of IgG2a and lower levels of IgG2b compared to C57BL/6
(P < 0.05; unpaired Student’s t -test).
As up-regulation of certain cytokines in the tumor microen-
vironment can enhance or suppress tumor rejection, we next
assessed the cytokine production of splenocytes from naïve mice,
mice given a single IP injection of DFTD and mice given two
IP injections of DFTD cells. Splenocytes were obtained from the
mice and incubated in vitro for 72 h with DFTD cells and the
supernatant analyzed for cytokines. Cytokine levels expressed into
the growth media were then measured.
Splenocytes from non-immunized mice did not produce
detectable cytokines. Evidence for IFN-γ, TNF, IL-6, and IL-10
production was apparent for splenocytes obtained at 4 and 21 days
following a single immunization (Figure 8). These same cytokines
were also detected when splenocytes were obtained 5 days after a
secondary DFTD immunization.
Of the TH1 cytokines, peak levels of IFN-γ and TNF-α were
detected from splenocytes obtained at day 21 after a single immu-
nization. Peak levels of the TH2 cytokine IL-10 were detected
following a secondary immunization. The pro-inflammatory
cytokine IL-6 followed a similar pattern to IL-10 with peak values
occurring after a secondary immunization. IL-4 and IL-12 were
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FIGURE 5 | Following a single IP injection serum samples were
collected on day 4, 7, 16, and 24 (results shown in black).
Secondary immunization occurred on day 95 and serum was
collected 7 days later (results shown in white). Mean fluorescence
intensity ratio of samples compared to pooled naïve mouse serum
was used as a relative measure of antibody expression. Data
expressed as mean of three mice±SEM except day 4 and 7
primary response (n=4).
not produced at detectable levels and are therefore not shown.
The antibody and cytokine profiles did not suggest that immu-
nization with DFTD cells polarized the immune response toward
a TH1 or TH2 profile.
IRRADIATED CELLS RETAIN IMMUNOGENICITY WHILE SONICATION OR
FREEZE/THAW LYSATES HAVE REDUCED IMMUNOGENICITY
Inactivated DFTD cells that maintain their immunogenicity are
required for vaccine and immunotherapy trials. To determine the
best means of achieving this, BALB/c mice were injected twice IP
with DFTD cells. The cells were either viable or inactivated by irra-
diation, sonication, or rapid freeze/thawing. Serum was collected
for analysis of anti-DFTD antibodies by flow cytometry. Spleno-
cytes from DFTD immunized mice were co-cultured with DFTD
cells and the supernatant analyzed for cytokine expression.
Mice immunized with irradiated cells produced higher levels of
DFTD specific antibodies compared to sonicated and freeze/thaw
lysates. When cultured in vitro with DFTD cells, splenocytes from
mice immunized with sonicated or freeze/thaw lysates produced
lower levels of IFN-γ and TNF-α compared to splenocytes from
mice immunized with irradiated cells (Figure 9). Irradiation of
cells is the better method for inactivation because immunogenicity
is maintained.
DISCUSSION
Devil Facial Tumour Disease is a cancer that is transmitted from
host to host with 100% mortality and no known immunity. Lack of
surface MHC-I expression on the DFTD cancer cells (8) explains
the lack of allo-recognition. An inability to trigger an immune
response suggests that DFTD cells are non-immunogenic and
could be imperceptible to any immune system. This study focused
on the fundamental question of whether DFTD cells are immuno-
genic and therefore it should be possible to generate an immune
response against DFTD tumor cells. As access to Tasmanian dev-
ils is limited due to their endangered status and there are limited
reagents such as monoclonal antibodies, we conducted this study
in our mouse model of DFTD (12).
The ability to establish DFTD xenografts in immunocom-
promised NOD/SCID (12) mice but not in immunocompetent
BALB/c and C57BL/6 mice suggests that the DFTD cells are
immunogenic. To confirm that the failure to establish DFTD
xenografts in immunocompetent mice was a specific immune
system response, we evaluated antibody, cytokine, and cytotoxic
responses in BALB/c and C57BL/6 challenged with viable DFTD
cells.
Flow cytometric detection of DFTD cell surface specific anti-
bodies in the serum of BALB/c and C57BL/6 mice provided the
Frontiers in Immunology | Tumor Immunity May 2014 | Volume 5 | Article 251 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pinfold et al. DFTD tumor cells are immunogenic
FIGURE 6 | Splenocytes from naïve and immunized C57BL/6 mice were
evaluated for cytotoxic responses against DFTD cells. Immunized mice
were given IP injections on days 0 and 14 and splenocytes harvested on
day 21. DFTD target cells were labeled with CFSE and dead cells identified
with PI staining. Flow cytometry was used to calculate cell mediated
cytotoxicity as a percentage of CFSE labeled DFTD target cells.
Splenocytes from naïve (n=4) or immunized (n=5) mice and DFTD target
cells were incubated for 18 h in vitro at 37°C with 5% CO2. Results
represent the mean and standard deviation of the combined cytotoxicities
of all mice with four technical replicates for each mouse.
most robust method for detection of an immune response follow-
ing immunization with DFTD tumor cells. There was no evidence
for substantial levels of preformed antibodies as serum from naïve
mice showed minimal binding to DFTD cells. This low level
of binding could have been due to low concentrations of pre-
formed antibodies, or simply non-specific binding. This suggests
that hyperacute xenograft rejection, which depends on preformed
antibodies, was unlikely to be the major cause preventing DFTD
establishment.
The SC injection route for immunizations had originally been
selected because of its similarity to the transfer of DFTD cells
in the Tasmanian devil population. By comparing single versus
multiple site SC injections, it was established that multiple site
injections produced a more intense antibody response. This was
most likely due to the targeting of an increased number of draining
lymph nodes. Although implantations at a single site may occur
frequently in wild Tasmanian devils, multiple site injections would
be more effective in a vaccination program. IP injections pro-
duced an even greater and more consistent antibody response. The
enhanced immunological response via the IP route in the mouse
model may have implications for the induction of a protective
immune response in Tasmanian devils. IP injections of vaccines
for Tasmanian devils may prove more effective than SC injections.
Additionally, when DFTD cells need to be inactivated for vac-
cine trials irradiation is preferable to sonication or freeze/thawing
FIGURE 7 | Cohorts of BALB/c and C57BL/6 mice were injected with
106 DFTD cells by IP injection on Day 0, with a second injection
between day 14 and 16; serum was collected 7–8days later. While
anti-DFTD antibody expression varied between individuals there was a
consistent trend that BALB/c mice were skewed toward higher levels of
IgG2a and lower levels of IgG2b compared to C57BL/6 mice (Data are
expressed as mean±SEM, probability calculated by unpaired Student’s
t -test, **P <0.01).
because the irradiated cells retain their immunogenicity in the
mouse model and it is reasonable to presume this would translate
to the Tasmanian devil’s responses.
Intraperitoneal injections generated both IgM and IgG
responses to the DFTD cells. The switch from IgM to IgG was
detected 4 and 7 days after the first immunization with DFTD
cells. This is consistent with a T cell dependent antibody response
to any cellular antigen. Secondary responses after a second DFTD
immunization following a 95-day rest revealed an amplified IgG
response. Consequently antibody responses to DFTD cells are
characteristic of a typical T cell dependent humoral immune
response to a cellular antigen.
The cell mediated arm of the immune response was evalu-
ated with an in vitro cytotoxicity assay. Splenocytes from DFTD
immunized mice produced the same level of cytotoxicity as spleno-
cytes from naïve mice. This suggests that the response did not
benefit from priming of cytotoxic T lymphocytes of the specific
immune system. Cytotoxicity may be mediated by NK, NKT cells,
or unprimed T cells responding to xenogeneic determinants. The
significance of this finding is twofold. Cytotoxic cells can recog-
nize DFTD cells and they can be killed. The relevance of this latter
point is that as DFTD cells are susceptible to killing by murine
cells they should also be susceptible to killing by cytotoxic cells of
the Tasmanian devil.
Devil Facial Tumour Disease cells do not express surface MHC-
I molecules (8) and therefore should be targets for NK cells. If NK
cells from the mouse are the effector cells, this suggests that DFTD
cells express the obligatory activating receptors. We have evidence
that Tasmanian devils have NK cells (13). If mouse NK-like cells
can bind to and destroy the DFTD cell in vivo then NK cells of
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FIGURE 8 | Cytokine production by splenocytes from naïve mice or
DFTD immunized mice, cultured in vitro with DFTD cells for 72h.
Primary responses refer to mice given a single injection of 2×106 DFTD
cells and day refers to time post immunization. Secondary responses refer
to mice immunized with 2×106 DFTD cells, rested 57 days, given a
second immunization with 2×106 DFTD cells and splenocytes collected
5 days later. Data expressed as mean of five mice±SEM except naïve
responses (n=3).
the Tasmanian devil should also have the capacity to kill DFTD.
The mechanism by which the DFTD cells inhibit or circumvent
the NK cells of Tasmanian devils following allograft transmission
of DFTD remains unknown.
With regards to NKT cells, they do not require MHC-I mole-
cules for binding but are activated by glycolipid antigens binding to
CD1d (14, 15). We have previously stated that β2-microglobulin is
down-regulated, which is an obligatory molecule associated CD1d
molecules making NKT cells unlikely effector cells. However, as
β2-microglobulin expression can be restored in the presence of
cytokines (8), NKT cells could have contributed to the immune
response. It is not currently known if DFTD cells express glycolipid
antigens capable of activating NKT cells.
The isotype switching of B cell antibody production is T cell
dependent and directed by T cell derived cytokines resulting in
antibody isotypes characteristic of either a TH1 or TH2 profile
(16–18). Although an immune response against DFTD cells was
demonstrated, we considered the possibility that DFTD could be a
tumor cell line that biases the immune response to a TH2 response.
This would permit tumor surveillance escape by suppressing TH1
anti-tumor responses (9, 19). This was analyzed by evaluating
cytokines. IFN-γ, characteristic of a TH1 response (20), was up-
regulated within days of immunization with DFTD cells. This was
followed by a strong and persistent up-regulation of IL-10, which
is a TH2 type cytokine that counterbalances the TH1 responses
generated by IFN-γ (20). IL-10 also promotes the activation and
proliferation of antigen-specific B cells (9). The timing of IL-10
up-regulation is also consistent with the detection of IgG antibod-
ies against DFTD cells in the mice. As IgG isotypes discriminate
between TH1 and TH2 responses (20), these were evaluated in the
BALB/c and C57BL/6 mice. Inoculation with DFTD cells did not
skew the immune response of either strain toward a TH1 or a TH2
response. There was some skewing toward IgG2a in the BALB/c
mice and toward IgG2b in the C57BL/6 mice. Both strains of mice
expressed high levels of IgG1, which is regarded as a TH2 response.
The relevance of these findings is that the DFTD cells do not con-
sistently bias the immune response toward a non-protective TH2
response.
As with results derived from any animal or in vitro model,
there will be limitations and the immunological mechanisms
observed may not translate to the natural host species. The com-
bined cytokine and antibody profile in these mice demonstrates
a humoral response to DFTD, which is consistent with xenograft
rejection mechanisms involving NK cells (21). Xenograft rejec-
tions are MHC-I independent and allograft rejections are based
upon MHC-I incompatibilities. DFTD cells do not express surface
MHC-I (8) and therefore cannot be rejected by MHC incompat-
ibilities. Rejection must therefore rely on other cell types such
as NK cells or NKT cells. NK cells are the most likely cell type
involved in the rejection of the DFTD xenograft described in this
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FIGURE 9 | Mice immunized with sonicated or freeze/thaw DFTD
cells produced lower levels of anti-DFTD antibody and lower levels
of IFN-γ andTNF-α compared to mice immunized with viable or
irradiated DFTD cells (Data are expressed as mean±SEM, probability
calculated by unpaired Student’s t -test, *P <0.05, **P <0.01, and
***P <0.001).
paper. Clearly, Tasmanian devil NK or NKT cells are not target-
ing the DFTD tumor cells. But as mouse cells can target DFTD,
immunogenic membrane signals would be present to act as targets.
In conclusion, the main finding of this study is that DFTD cells
are suitable targets for immunotherapy. There is a need to develop
a vaccine or treatment to prevent extinction of the Tasmanian devil
in the wild and various strategies can be trialed in the mice before
moving to clinical trials with Tasmanian devils.
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